How is ESR used in the clinical staging/risk classification of classical Hodgkin Lymphoma in pediatric and adult patients?
The current NCCN guideline version 2.2021 is a little confusing. On page HODG-2, the clinical staging/risk classification did not include ESR, but on page HODG-4 and HODG-B, it says "NCCN Unfavorable Factors include bulky mediastinal or >10 cm disease, B symptoms or ESR>=50, and > 3 sites of disease."
Community PollStarted
Do you use ESR as part of the clinical staging/risk stratification for classical Hodgkin lymphoma?
17 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Pediatric Hematology/Oncology · Aflac Cancer and Blood Disorders Center/ Children's Healthcare of Atlanta - Egleston
Answered on
There has not been a consistent initial risk classifier for childhood Hodgkin Lymphoma (in contrast to the IPS used in adults). ESR has been used to follow patients in terms of a trend if elevated at diagnosis and that continues to be suggested by the current pediatric guidelines. Schwartz et al., (...
Join for free or sign in to see the full answer